Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.
about
A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosisEndless Resistance. Endless Antibiotics?Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.In-silico Metabolome Target Analysis Towards PanC-based Antimycobacterial Agent Discovery.Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.The tuberculosis drug discovery and development pipeline and emerging drug targets.Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.Tuberculosis drug discovery and emerging targets.New structural classes of antituberculosis agents.The pseudo-Michael reaction of 1-aryl-4,5-dihydro-1H-imidazol-2-amines with ethyl ethoxymethylenecyanoacetate.Synthesis, central nervous system activity, and structure-activity relationship of 1-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones.Antimycobacterial activity of nitrogen heterocycles derivatives: 7-(pyridine-4-yl)-indolizine derivatives. Part VII8-12.Design, Synthesis and Antimycobacterial Activity of Novel Imidazo[1,2-a]pyridine Amide-Cinnamamide Hybrids.A Convenient Synthesis of C-3-Aryloxymethyl Imidazo[1,2-a]Pyridine DerivativesSuperparamagnetic CuFeO2Nanoparticles in Deep Eutectic Solvent: an Efficient and Recyclable Catalytic System for the Synthesis of Imidazo[1,2-a]pyridines
P2860
Q28485999-B44D3797-7AB6-443C-AD3E-43DE73CF0E17Q28822179-7564E6B1-BD8B-4349-A330-F1CC96AF4163Q33894015-BF38E0A2-BD04-49D2-AB35-F19A5A910E17Q34596981-B227647B-C651-479A-BE32-E829BE9B4139Q35538689-7CB3E359-A20F-4BC0-A2B7-0FF081349F92Q35589896-40580C3A-3FC4-4FEC-9F8D-D3C1C35BE81DQ35664209-E42246E0-ED98-4506-B886-B3F27EBED4B0Q37069968-403EB7C0-5CCF-4EDD-8566-D81E991C94F4Q38219605-597078E7-5A6A-4120-94B5-44E93DFC1B6FQ39362128-233EA6B1-2A90-4C69-9427-F98ADF7088CEQ40745786-9C5D62A2-8227-4F31-8259-9CB24D394CB9Q41828638-3EB876D8-4D7C-4AB2-B9C2-9AD4A79061CCQ50087921-300F5F96-616D-40F9-A8F2-1427BF18B334Q50205820-C821887E-7C45-4EAD-AFE1-FA0C36219163Q59009532-CA855E41-BCBC-4D13-95B0-1E7F328CE27DQ59190897-4235C757-21C1-49F9-861B-98C410389CDD
P2860
Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@ast
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@en
type
label
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@ast
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@en
prefLabel
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@ast
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@en
P2093
P2860
P1476
Generation and exploration of ...... isomeric 5,6-fused scaffolds.
@en
P2093
Chang Hwa Hwang
Helena Boshoff
Lowell D Markley
Marvin J Miller
Mayland Chang
Sanghyun Cho
P2860
P304
P356
10.1016/J.BMC.2012.02.025
P407
P577
2012-02-16T00:00:00Z